您的购物车当前为空
Terazosin, a quinazoline derivative, is an orally active and competitive antagonist of α1-adrenoceptors. Its mechanism of action involves relaxing blood vessels and promoting bladder opening. Terazosin exhibits therapeutic potential for treating benign prostatic hyperplasia (BPH) and high blood pressure [1][2][3].
Terazosin, a quinazoline derivative, is an orally active and competitive antagonist of α1-adrenoceptors. Its mechanism of action involves relaxing blood vessels and promoting bladder opening. Terazosin exhibits therapeutic potential for treating benign prostatic hyperplasia (BPH) and high blood pressure [1][2][3].

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 10,600 | 1-2周 | |
| 50 mg | ¥ 13,800 | 1-2周 | |
| 100 mg | ¥ 17,500 | 1-2周 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | Terazosin, a quinazoline derivative, is an orally active and competitive antagonist of α1-adrenoceptors. Its mechanism of action involves relaxing blood vessels and promoting bladder opening. Terazosin exhibits therapeutic potential for treating benign prostatic hyperplasia (BPH) and high blood pressure [1][2][3]. |
| 体外活性 | Terazosin does not discriminate cloned α1-adrenoceptor subtypes transiently expressed in COS cells [1]. |
| 体内活性 | Terazosin can be used to promote stone discharge in treatment of ureteral stones. Terazosin is reportedly safe and effective in treatment of distal ureteral stones, especially stones >5 mm [3]. |
| 分子量 | 387.43 |
| 分子式 | C19H25N5O4 |
| CAS No. | 63590-64-7 |
| Smiles | NC=1C2=C(N=C(N1)N3CCN(C(=O)C4CCCO4)CC3)C=C(OC)C(OC)=C2 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多